In patients with colchicine-resistant familial Mediterranean fever (crFMF), open-label treatment with canakinumab (150 or 300 mg every 4 or 8 weeks, with individually adjusted dose regimens) continued to control disease activity from week 40 in the phase III CLUSTER trial. During a 72-week period (weeks 41 to 113 of the trial), >90% of the treated patients experienced no flares or had one flare, whereas a median of 17.5 flares per year was reported for the patients before entering the trial. The median C-reactive protein serum values remained low, and no new or unexpected adverse events were reported.
References
Original article
Ozen, S. et al. Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2020-217419 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McHugh, J. Long-term efficacy of canakinumab in crFMF. Nat Rev Rheumatol 16, 408 (2020). https://doi.org/10.1038/s41584-020-0466-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-020-0466-5